ArticleDiscover oncology2025
Multiomic analysis of CCNE1 amplification associated molecular and immune features in gynecological cancers.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CCNE1: A Cell Cycle Regulator That Influences Tumor Progression.Cancer medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo delineate the genomic and cellular features of CCNE1 amplification across gynecologic cancer types using large-scale multi-omics data and assess its relevance for patient stratification and therapeutic targeting.
methodsWe analyzed genomic and transcriptomic data from 12,845 patients with gynecological cancers curated from the cBioPortal database, including ovarian, endometrial, and cervical carcinomas. CCNE1 amplification rates, cooccurring genomic alterations, and pathway enrichment were evaluated. Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomic data from cervical, endometrial, and ovarian tumors were used to investigate CCNE1 expression patterns, cell type specificity, and microenvironmental interactions.
resultsCCNE1 amplification was detected in 8.40% of all patients, with the highest rates in patients with ovarian cancer (8.01%) and endometrial cancer (5.06%). Among the ovarian subtypes, carcinosarcoma showed the highest amplification frequency (12.46%), followed by high-grade serous carcinoma (9.84%). Amplified tumors are frequently co-altered by TP53, PIK3CA, and PI3K-AKT pathway genes. Single-cell analyses revealed that CCNE1 expression was largely confined to epithelial cells and was associated with proliferative and structural remodeling pathways, with limited immune engagement across tumor types. Spatial transcriptomics confirmed the localization of CCNE1 in epithelial-rich regions and its correlation with adhesion- and motility-related genes in clear cell and high-grade serous ovarian carcinomas.
conclusionCCNE1 amplification is enriched in aggressive histologic subtypes of gynecological cancers and is linked to epithelial-specific expression and immune exclusion. These findings indicate that CCNE1 represents a potential molecular marker for tumor aggressiveness, warranting further investigation in the context of patient stratification and therapeutic targeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.